BRPI0414798A - métodos para usar aminoácidos com afinidade para a proteìna alfa2delta - Google Patents

métodos para usar aminoácidos com afinidade para a proteìna alfa2delta

Info

Publication number
BRPI0414798A
BRPI0414798A BRPI0414798-7A BRPI0414798A BRPI0414798A BR PI0414798 A BRPI0414798 A BR PI0414798A BR PI0414798 A BRPI0414798 A BR PI0414798A BR PI0414798 A BRPI0414798 A BR PI0414798A
Authority
BR
Brazil
Prior art keywords
amino acids
protein
methods
disorders
affinity amino
Prior art date
Application number
BRPI0414798-7A
Other languages
English (en)
Inventor
Candace Roskoph Bramson
George Michael Haig
Denis J Schrier
Fong Wang
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0414798A publication Critical patent/BRPI0414798A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

"MéTODOS PARA USAR AMINOáCIDOS COM AFINIDADE PARA A PROTEìNA ALFA2DELTA". Esta invenção relaciona-se com certos <225>-aminoácidos que se ligam à sub-unidade alfa-2-delta ((x2S) de um canal de cálcio. Estes compostos e seus sais farmaceuticamente aceitáveis são úteis no tratamento de uma variedade de distúrbios psiquiátricas, dor e outras distúrbios.
BRPI0414798-7A 2003-09-25 2004-09-13 métodos para usar aminoácidos com afinidade para a proteìna alfa2delta BRPI0414798A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50600303P 2003-09-25 2003-09-25
PCT/IB2004/002978 WO2005030184A2 (en) 2003-09-25 2004-09-13 Therapeutic beta aminoacids

Publications (1)

Publication Number Publication Date
BRPI0414798A true BRPI0414798A (pt) 2006-11-21

Family

ID=34393101

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414798-7A BRPI0414798A (pt) 2003-09-25 2004-09-13 métodos para usar aminoácidos com afinidade para a proteìna alfa2delta

Country Status (15)

Country Link
US (2) US7112610B2 (pt)
EP (1) EP1670452A2 (pt)
JP (1) JP2007506726A (pt)
KR (1) KR100774625B1 (pt)
CN (1) CN1856301A (pt)
AU (1) AU2004275572A1 (pt)
BR (1) BRPI0414798A (pt)
CA (1) CA2539976A1 (pt)
IL (1) IL173862A0 (pt)
MX (1) MXPA06003381A (pt)
NO (1) NO20061801L (pt)
RU (2) RU2344121C2 (pt)
TW (1) TW200511989A (pt)
WO (1) WO2005030184A2 (pt)
ZA (1) ZA200602450B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2836449C (en) 2011-05-17 2021-04-27 The Regents Of The University Of California Kinase inhibitors
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
SI2710005T1 (sl) 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze
SI3181567T1 (sl) 2012-09-10 2019-09-30 Principia Biopharma Inc. Spojine pirazolopirimidina, kot inhibitorji kinaze
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
MX2016010754A (es) 2014-02-21 2017-03-03 Principia Biopharma Inc Sales y forma solida de un inhibidor btk.
MA41197B1 (fr) 2014-12-18 2021-01-29 Principia Biopharma Inc Traitement de le pemphigus
EP3313839A1 (en) 2015-06-24 2018-05-02 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP3478273A1 (en) 2016-06-29 2019-05-08 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
FR2791982B1 (fr) * 1999-04-06 2002-12-27 Inst Nat Sante Rech Med Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques.
MXPA03008164A (es) * 2001-03-13 2003-12-12 Univ Kingston Agentes anti-epileptogenos.
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss

Also Published As

Publication number Publication date
WO2005030184A3 (en) 2005-06-02
RU2006107650A (ru) 2007-10-27
NO20061801L (no) 2006-06-02
CA2539976A1 (en) 2005-04-07
JP2007506726A (ja) 2007-03-22
AU2004275572A1 (en) 2005-04-07
CN1856301A (zh) 2006-11-01
IL173862A0 (en) 2006-07-05
EP1670452A2 (en) 2006-06-21
US20060247282A1 (en) 2006-11-02
KR20060056391A (ko) 2006-05-24
US7112610B2 (en) 2006-09-26
MXPA06003381A (es) 2006-06-08
RU2344121C2 (ru) 2009-01-20
KR100774625B1 (ko) 2007-11-08
US20050124669A1 (en) 2005-06-09
RU2008137379A (ru) 2010-03-27
ZA200602450B (en) 2007-09-26
TW200511989A (en) 2005-04-01
WO2005030184A2 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
BR0308814A (pt) Aminoácidos com afinidade para a proteìna-alfa2gama
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
BR0315157A (pt) Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
CR8290A (es) AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2-d
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
NO20061801L (no) Fremgangsmater for anvendelse av aminosyter med affinitet for alfa-2-deltaproteinet
EA200300532A1 (ru) Способ и состав для связывания ацетальдегида в слюне, желудке и толстой кишке
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BRPI0414819A (pt) pró-fármacos de aminoácidos com afinidade para a proteìna alfa2delta
DK1553985T3 (da) Biphenyler som billeddannelsesmiddel i forbindelse med Alzheimers sygdom
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
BRPI0513028A (pt) preparação de beta-aminoácidos tendo afinidade para a proteìna alfa-2-delta
DOP2004001000A (es) Aminoacidos con afinidad por la proteina
UY29033A1 (es) Aminoácidos con afinidad por la proteína a2o (alfa 2 delta)
DOP2003000616A (es) Aminoacidos con afinidad por la proteina a2
BR0314525A (pt) Composições e métodos para tratamento de disfunção sexual

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.